During radiotherapy 80% to 90% of all patients will develop some degree of infl ammation symptoms, such as erythema, dry or wet desquamation, skin folds, or mucositis depending on radiation-and patient-related factors and the extent of irradiated skin or mucosal areas. Up to now radiation induced local reactions represent still an important toxicity factor. Cutaneous and mucosal side eff ects may reduce the patient's compliance and can be limiting factors to follow radiotherapy protocols. Th erefore, there is a high need for eff ective prophylactic and therapeutic treatments. Basically, guidelines recommend the avoidance of mechanical, chemical and thermal irritants, especially the exposure to high temperatures. To delay onset of radiodermatitis various preventive topicals may be applied like aqueous cream formula with or without antioxidative agents. In general, the treatment of radiodermatitis primarily should maintain moisture and skin permeability and consists of hydrophilic creams, antioxidative and antiinfl ammatory topicals. Hydrocolloid dressings may reduce and improve wound healing in grade 2 and 3 reactions. Supportive therapy of radiation-induced mucositis includes the maintenance of oral care protocols and adequate nutrition during the course of treatment. A suffi cient oral health status is one of the most important factors for prevention of severe oral complications. Th e MASCC guidelines recommend furthermore the use of non-medicated rinses with saline or sodium bicarbonate 4 to 6 times daily. Further approaches suggest the use of local anaesthetics and systemic analgesics for severe mucositis. Besides local preventive agents and supportive care protocols, modern radiation treatment techniques remain the most promising intervention in reducing the degree of skin reactions.
Introduction
Infl ammatory skin reactions and mucositis are common toxicities in cancer patients undergoing radiotherapy.
Especially radiation induced mucositis in head and neck cancer patients remains a frequent side eff ect because of the more aggressive irradiation schedules. Furthermore concurrent application of chemotherapy and/or epidermal growth factor receptor (EGFR) targeted therapy does increase not only the therapeutic effi cacy but also the frequency of side-eff ects signifi cantly.
Oral mucositis grade I-II may aff ect more than 95% of head and neck cancer patients. Th e oral complications are often accompanied by pain and dysphagia and may become a dose limiting toxicity resulting in an unfavourable outcome of therapy. Th erefore an intensive prophylactic and therapeutic supportive care management is warranted.
During exposure to therapeutic irradiation the most frequent complications are erythema and edema. It is estimated that more than 90% of patients undergoing curative irradiation with total doses >55 Gy will develop a radiodermatitis and approximately 10% of these patients encounter a grade 3 skin lesion before the scheduled end of RT [10] . Especially cutaneous side eff ects may both reduce the patient's compliance and quality of life. Preventive treatments are usually based on clinical experience and diff er considerably between departments. Th e goal of management is to identify the patient at risk and to adopt strategies to delay onset of skin reactions.
Supportive care and treatment recommendations
Radiodermatits Th e reaction of the skin to ionising radiation is highly complex and depends on numerous radiation-related, treatmentrelated, and patient-related factors. Previous studies [13] have tried to identify factors associated with an increased risk of acute radiation-induced toxicity. Th ese include large irradiation volume, concomitant systemic treatment and comorbidities such as diabetes or hypertension. Treatment areas commonly sited as having a higher incidence of side-eff ects are those of head and neck, breast and chest wall fi elds and regions containing skin folds [1] .
Th e patho-physiology of radiation-induced skin morbidities is understood as a secondary infl ammatory reaction, possibly from the release of free radicals producing doubleand single-strand DNA breaks [6] . Acute cutaneous side-effects are defi ned as occurring within the fi rst 6 months of therapy. Th e signs of toxicity are classifi ed according to the Radiotherapy Oncology Group criteria (RTOG: acute skin radiation morbidity scoring criteria) [4] . Grade 1 toxicity is not usually experienced until total radiation doses of 20 to 25 Gy.
During radiotherapy 80% to 90% of patients will develop some degree of infl ammation symptoms, such as erythema, dry desquamation, moist desquamation pitting or oedema. In severe cases painful ulceration or necrosis may occur [1, 4] .
Clinically, acute radiodermatitis presents as localised or confl uent erythema, which seems to be correlated mostly with changes in arterioles. Th is obstruction leads to dermal infi ltration and interstitial oedema. Th erefore mechanically irritation of the dermis, sun exposure and skin traumas should be completely avoided. Several studies [14, 18] have shown that washing did not worse skin infl ammation. Gentle washing should be permitted especially for patient's personal comfort.
Up to now the German guideline [21] does not recommend any prophylactic agents to prevent radiodermatitis. Diff erent preventive recommendations are discussed controversially in the literature [3, 26] . Th ere are various concepts depending on personal preferences and institutional policy mainly based on retrospective data. Comparative studies did not demonstrate any improved prophylactic eff ect using hydrophilic emulsions with additional topicals such as trolamine, sucralfate, Th eta Crème or aloe vera [6, 16, 21] . Th e majority of studies compared agents just in a retrospective setting. Recent trials suggest that antioxidative and anti-infl ammatory products such as calendula and corticosteroids may have prophylactic impact in skin care [22] . Th e largest randomised evaluation of over 300 breast cancer patients demonstrated a signifi cant reduction in grade 2/3 dermatitis, comparing the eff ectiveness of calendula versus trolamine. In this randomised trial 30% of patients found calendula difficult to apply due to its more solid consistence and was not recommended at the end [15] . Two clinical studies [3, 22] reported that low dose corticosteroids may be benefi cial in reduction of itching and irritation. Infl ammatory process may be alleviated, but skin thinning and skin atrophy may pose a problem using steroid topicals over a period of 8 weeks.
Actually, reports demonstrated fi rst promising results using antioxidative agents such as silymarin or MAS065D (XClair®) in breast cancer patients. Th e benefi cial eff ects of silymarin-based cream in reducing the rate of objective and subjective skin toxicity have been confi rmed in one prospective trial evaluating 101 breast cancer patients [1] . Besides local agents modern radiation treatment techniques remain the most promising intervention in reducing the degree of skin reaction.
Th erapeutic management of acute skin toxicity is based on clinical experience due to the inconsistencies in the clinical management and the absence of randomised trials [21] . Erythema grade 1 should be treated by hydrophilic cream to increase the skin's moisture and maintain skin permeability. [3] . Low dose corticosteroids (1%) may reduce the severity of toxicity in case of itch, pain and burning. Up to now there is insuffi cient evidence to recommend specifi c dressings. Nevertheless silicon foam dressings have been shown to be eff ective compared to standard aqueous cream in breast cancer patients suff ering from erythema in one observational trial [5] . Mean size of moist desquamation and ulceration was signifi cantly smaller in patients receiving hydrocolloid dressings. Furthermore pain control and patient comfort did increase signifi cantly in patients treated with hydrocolloid dressings for acute skin infl ammation grades 2 and 3 [11] . In case of superinfection local antiseptics are indicated to eliminate the toxin, in severe cases systemic antibiotics should be used [26] . Chronic skin changes, such as necrosis and ulceration should be treated similar to those principles for burns and sometimes may require skin grafting. Th ere are case reports suggesting that hyperbaric oxygenation may be safe and eff ective in managing radiation-induced late side-eff ects, such as soft tissue necrosis [20] . Th e summary of clinical suggestions for care of patients with radiodermatitis is shown in Table 1 .
Radiation induced mucosal injury of the oral cavity and head and neck region
Radio ± chemotherapy of the head and neck region may lead to infl ammatory skin and mucosal reactions. Th e rapidly proliferating basal cells of the mucosal tissue are extremely radiosensitive. Two to three weeks after initiation of radiotherapy mucosal cell death of the basal tissue cause superfi cial ulcerations. Th e generation of free radicals by radiation results in DNA strand breaks. Furthermore in these cells activation of transcription factors such as NF kappa B leads to the up-regulation of genes that modulate apoptosis processes. Direct and indirect epithelial stem cell deaths result in a loss of repopulation capacity and support mucosal surface damage [23, 24] .
Th e incidence of mucositis is infl uenced by numerous radiation-related factors and has been shown to arise with the total treatment dose, especially in patients receiving more than 50 Gy. Modern irradiation schedules using dose-escalation and acceleration are associated with higher toxicity rates in 29-45% of cases [24] . Oral mucositis occurs more often in patients receiving therapy for oropharyngeal or nasopharyngeal cancer concomitant to chemotherapy [8] . Pretreatment of cancer with induction chemotherapy may also alter the tol- erability of irradiation rendering skin and mucosa more susceptible to side-eff ects [7] . Mucositis grade I/II has now become one of to most important non-hematological toxicity aff ecting more than 90% of patients. Mucosal erythema is frequently followed by edema and ulceration, ranging from aphthous-like lesions to generalised desquamation. Infl ammation may occur limited in range or can involve up to more than 50% of the oral cavity, most commonly in patients receiving combined therapy [8] . Mucosal ulceration may induce pain and dysphagia. Radiation-induced aff ection of the salivary glands contributes to xerostomia and reduces an important barrier against oral infections. Th is may lead to the reduced intake of oral nutrition resulting in the need for parenteral nutrition, feeding tube dependence, dehydration, weight loss and potentially severe infections and aspiration [12] .
Prevention of oral mucositis includes the maintenance of oral care protocols and adequate nutrition during the course of treatment. Prophylactic percutaneous gastrostomy tube has been shown to be benefi cial in patients receiving curative high dose radio-chemotherapy [8, 9] .
A suffi cient oral health status is important to reduce the incidence of severe oral complications. Prior to cancer therapy oral and teeth disorders such as dental plaque formation, periodontal diseases or other pathological sources of gingival irritation should be treated. Patients should avoid irritants such as alcohol and tobacco use. Oral hygiene measures such as soft tooth brushing and mouthwashes are recommended [17] . Th e RTOG and MASCC/ISOO [8] guidelines recommend furthermore the use of non-medicated rinses with saline or sodium bicarbonate 4 to 6 times daily. Non-randomised trials reported about 30 to 40% reduction in stomatitis for patients, who followed a daily preventive protocol with chlorhexidine (0.2%) [19] . In a randomised clinical trial [23] preventive antimicrobial medication did not reduce the incidence of mucositis and is not recommended in the prophylactic setting.
Mouth rinses with anti-infective, antiphlogistic and anesthetic properties have been evaluated in several clinical studies, if mucositis develops [12] . In cases of superinfection antimicrobial topical agents such as amphotericin B or clotrimazole are usually curative. Because of the insuffi cient evidence of benefi t, the guidelines of the MASCC do not recommend the use of radioprotective agents such as amifostine in head and neck cancer patients. Amifostine, as normal tissue protector during cytotoxic therapy, has been proven to reduce proctitis for rectal cancer patients only [2] . Topical benzydamine may be eff ective in pain control. It inhibits proinfl ammatory cytokines including TNF alpha and is characterised by non-steroidal anti-infl ammatory, anesthetic and antimicrobial properties. Based on a multicenter randomised trial in head and neck cancer patients benzydamine is recommended in patients receiving moderate-dose adjuvant radiotherapy [9] . A favoured local mouth wash consists of antacid, diphenhydramine, to which lidocaine is added. Local formula with analgesic often has to be combined with systemic analgesics, including opiods for suffi cient pain relief. Medication with antiulcerative properties such as prostaglandine or pentoxifylline were investigated with a marginal eff ect on mucositis. Growth factors, which not only stimulate precursor cells in the bone marrow but also aff ect the proliferation of other epithelial cells, have been applied for the management of oral mucositis. Palifermin (recombinant keratinocyte growth factor-1) reduced the incidence of grade 3 and 4 toxicities in patients with hematologic malignancies. Up to now this agent is currently under investigation in prospective trials including head and neck cancer patients [25] .
Th e summary of evidence-based clinical practice guidelines for care of patients with oral mucositis during radiotherapy is shown in Table 2 .
Role of irradiation technique
Up to now acute radiodermatitis and mucositis represent still an important toxicity factor for cancer patients, as it may cause important deterioration of the quality of life and patient's compliance with potential negative impact on RT treatment effi cacy [21] . Using new technology and hyperfractionation schedules, the therapeutic ratio has been improved while the potential morbidity has decreased.
Modern radiation techniques, especially photon beams of higher energy, reduce skin dose, which provides better normal tissue protection [14] . Clinically the emphasis has been made on developing immobilisation procedures for protecting organs at risk. Mucosal side eff ects can be reduced signifi cantly fi lling bolus materials between metallic dental restorations to minimise the dose from scattered radiation.
Th e introduction of individual immobilisation by means of mask-fi xation may result in a relevant decrease in the uncertainty due to breathing motion and daily positioning errors. Especially diagonal thermoplastic materials are recommended for breast cancer patients to avoid bolus effects. To improve dose homogeneity and to avoid high doses in contiguous skin surface styrofoam wedge is indicated for pendulous breasts.
Modern radiation techniques such as 3D conformal therapy and IMRT (intensity modulated radiotherapy) allow to avoid 'hotspots' [14] and to reduce normal tissue reactions in a substantial number of patients. Th e new 'Rapid Arc' technology' is characterised by volumetric arcs that deliver a precisely sculpted 3D dose distribution with a single 360-degree rotation of the linear accelerator gantry and optimises dose conformity while signifi cantly shortening treatment times. Recently, the value of high energy particles (protons) instead of X-rays (photons) is under investigation to minimise treatment sequela.
Conclusion
Although marked progress has been achieved in the management of side eff ects, further improvement is needed to optimise the supportive care management for cancer patients. Furthermore, research might focus on new strategies to prevent overall toxicity, by selecting the systemic treatment on tumour cells and protecting organs at risk in radiotherapy planning procedures. In future, further technical innovations are essential for the prevention of radiation toxicity.
Confl ict of interest
Th e authors declare that there is no confl ict of interest.
